• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SONIDEGIB Drug Record

  • Summary
  • Interactions
  • Claims
  • SONIDEGIB chembl:CHEMBL2105737 ApprovedAntineoplastic

    Alternate Names:

    LDE 225
    NVP-LDE 225
    NVP-LDE-225
    NVP-LDE225
    SONIDEGIB
    LDE-225
    LDE225
    ERISMODEGIB
    ERISMODEGIB (DELETED INN)
    N-[6-(CIS-2,6-DIMETHYLMORPHOLIN-4-YL)PYRIDIN-3-YL]-2-METHYL-4'-(TRIFLUOROMETHOXY)[1,1'-BIPHENYL]-3-CARBOXAMIDE
    ODOMZO®
    rxcui:1659191
    chembl:CHEMBL2105737
    drugbank:09143
    chemidplus:956697-53-3
    pubchem.compound:24775005

    Drug Info:

    Drug Class Small molecule inhibitor
    FDA Approval Basal cell carcinoma
    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    (5 More Sources)

    Publications:

    Burness, 2015, Sonidegib: First Global Approval., Drugs
    Sharpe et al., 2015, Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma., Cancer Cell
    Danial et al., 2016, An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib., Clin. Cancer Res.
    Chen et al., 2016, Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma., Mol. Cancer Ther.
    Della Corte et al., 2015, SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer., Clin. Cancer Res.
    Kool et al., 2014, Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition., Cancer Cell
  • SONIDEGIB   SUFU

    Interaction Score: 24.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24651015


    Sources:
    CIViC

  • SONIDEGIB   PTCH1

    Interaction Score: 18.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24651015


    Sources:
    CIViC OncoKB

  • SONIDEGIB   SMO

    Interaction Score: 10.46

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Novel Target
    Trial Name LDE225
    combination therapy Gefitinib + Sonidegib

    PMIDs:
    26323341 25759019 26546616 26823493 26124204


    Sources:
    MyCancerGenome TdgClinicalTrial JAX-CKB CIViC MyCancerGenomeClinicalTrial TTD

  • SONIDEGIB   MYCN

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24651015


    Sources:
    CIViC

  • SONIDEGIB   EGFR

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gefitinib + Sonidegib
    Response Type no benefit
    Evidence Type Actionable

    PMIDs:
    26124204


    Sources:
    JAX-CKB

  • MyCancerGenome: ERISMODEGIB

    • Version: 20-Jun-2017

    Alternate Names:
    LDE225 Development Name
    ERISMODEGIB Generic Name

    Drug Info:
    Drug Class Small molecule inhibitor

    Publications:

  • MyCancerGenome: SONIDEGIB

    • Version: 20-Jun-2017

    Alternate Names:
    ODOMZO Trade Name

    Drug Info:
    Drug Class Small molecule inhibitor
    FDA Approval Basal cell carcinoma

    Publications:

  • TdgClinicalTrial: ERISMODEGIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • JAX-CKB: Sonidegib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Della Corte et al., 2015, SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer., Clin. Cancer Res.
    Danial et al., 2016, An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib., Clin. Cancer Res.
    Chen et al., 2016, Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma., Mol. Cancer Ther.

  • CIViC: SONIDEGIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Kool et al., 2014, Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition., Cancer Cell
    Della Corte et al., 2015, SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer., Clin. Cancer Res.

  • TTD: LDE225

    • Version: 2020.06.01

    Alternate Names:
    D09BNZ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL2105737

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: LDE225

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Sonidegib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21